Patient-Derived Gastric Cancer Assembloid Model Enhances Drug Response Studies

1. Study Background and Research Question

Gastric cancer remains a major therapeutic challenge, ranking as the fifth most diagnosed carcinoma and the second leading cause of cancer-related mortality globally. Patients with advanced or metastatic gastric cancer face a five-year survival rate below 10%, despite the availability of surgery, chemotherapy, radiotherapy, and targeted agents. This poor prognosis is largely attributed to pronounced tumor heterogeneity, which drives variable treatment responses and complicates the development of effective therapies. Traditional three-dimensional (3D) organoid models, while valuable for studying tumor biology, often fall short in replicating the complex tumor microenvironment, particularly the contribution of cancer-associated fibroblasts and other stromal cell types associated with poor prognosis and treatment resistance. The central research question addressed by Shapira-Netanelov et al. (2025) is whether a more physiologically relevant, patient-specific in vitro model can be developed by integrating tumor epithelial cells with matched stromal cell subpopulations to better understand tumor biology and drug response.

2. Key Innovation from the Reference Study

The primary innovation of the study is the development of a patient-derived gastric cancer assembloid model that faithfully recapitulates the cellular heterogeneity and microenvironment of individual tumors. By co-culturing tumor organoids with stromal subpopulations—derived from the same patient tissue and expanded in tailored media—the researchers created assembloids that include both cancerous epithelial cells and diverse stromal elements such as mesenchymal stem cells, fibroblasts, and endothelial cells. This approach enables the model to more accurately reflect the interactions and signaling dynamics present in vivo, overcoming limitations associated with monoculture organoid systems. Notably, the assembloid model supports patient-specific drug screening and allows for the investigation of resistance mechanisms mediated by the tumor stroma, which are often missed in conventional models (Shapira-Netanelov et al., 2025).

3. Methods and Experimental Design Insights

The study utilized freshly resected gastric tumor tissue, which was dissociated to yield heterogeneous cell populations. Cells were expanded in lineage-specific media to enrich for organoids (tumor epithelial cells), mesenchymal stem cells, fibroblasts, and endothelial cell subtypes. These subpopulations were subsequently recombined in defined ratios and co-cultured in an optimized assembloid medium that supports the growth and viability of each cell type. The resulting assembloids were analyzed using immunofluorescence staining to assess biomarker expression, as well as RNA sequencing to profile transcriptomic heterogeneity. Drug responsiveness was determined via cell viability assays following exposure to a panel of therapeutic agents.

Protocol Parameters

• Tumor dissociation: Enzymatic and mechanical dissociation to isolate viable single cells from gastric cancer tissue.
• Lineage-specific expansion: Use of tailored media formulations for organoid, mesenchymal stem cell, fibroblast, and endothelial cell outgrowth, ensuring preservation of subtype-specific features.
• Assembloid co-culture: Combination of expanded cell subtypes in optimized assembloid medium; ratios adjusted to reflect patient tumor composition when possible.
• Biomarker assessment: Immunofluorescence staining for epithelial and stromal markers; RNA sequencing for transcriptomic profiling.
• Drug response evaluation: Cell viability assays following treatment with chemotherapeutics and targeted agents; assessment of drug-specific and patient-specific effects.

4. Core Findings and Why They Matter

The assembloid model generated in this study successfully mirrors the cellular architecture and molecular heterogeneity of primary gastric tumors, as evidenced by the co-expression of epithelial and stromal markers. Compared with monoculture organoids, assembloids displayed elevated levels of inflammatory cytokines, extracellular matrix remodeling factors, and genes linked to tumor progression. Importantly, drug screening experiments revealed that while certain agents were effective in both organoid and assembloid models, others lost efficacy in the assembloid context. This highlights a critical role for stromal components in modulating drug response, and underscores the limitations of traditional organoid models for predicting clinical outcomes (reference study). The assembloid system thus provides a more rigorous platform for personalized drug testing, enabling the identification of resistance mechanisms that arise from tumor–stroma interactions.

5. Comparison with Existing Internal Articles

Several recent articles have explored the role of folate pathway modulation and stromal-tumor interactions in preclinical cancer models. For example, Leucovorin Calcium: Folate Analog for Methotrexate Rescue and Leucovorin Calcium in Tumor–Stroma Modeling: Redefining Methotrexate Rescue both highlight the utility of calcium folinate as a protective agent against methotrexate-induced cytotoxicity and as a mechanistic probe in studies of antifolate drug resistance and folate metabolism pathways. These articles emphasize Leucovorin Calcium's role in enabling robust modeling of drug resistance and tumor–stroma interactions, which aligns closely with the reference study's emphasis on the impact of stromal cells in modulating drug responses. However, the reference study advances this field by providing a systematically validated method for integrating autologous stromal components with patient-matched tumor organoids, thereby enhancing the translational relevance of preclinical research and enabling more accurate cell proliferation assays and drug screening workflows.

6. Limitations and Transferability

Despite its significant advances, the assembloid model described in the reference study has inherent limitations. The generation of assembloids requires access to freshly resected patient tumor tissue and specialized expertise in cell isolation and culture, which may limit scalability and immediate adoption across laboratories. Additionally, while the model improves on traditional organoid systems by incorporating stromal diversity, it may not fully capture other aspects of the tumor microenvironment such as immune cell subsets or vascularization. Furthermore, as with any in vitro system, findings derived from assembloids require validation in vivo before clinical translation. Nonetheless, the approach is broadly transferable to other solid tumor types and represents a valuable advance for antifolate drug resistance research and folate metabolism pathway studies.

7. Research Support Resources

For researchers seeking to model methotrexate rescue, investigate folate metabolism, or study protection from methotrexate-induced growth suppression in organoid or assembloid systems, high-purity reagents such as Leucovorin Calcium (SKU A2489) are recommended. Leucovorin Calcium is a widely used calcium folinate that offers reliable support for cell proliferation assays and translational oncology workflows, as noted in the internal literature. Proper storage at -20°C and prompt use of aqueous solutions are advised to maintain reagent stability and experimental reproducibility.